Clinical Trial: A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active

Brief Summary: The purpose of this study is to evaluate the effectiveness (improvement of signs and symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.